Literature DB >> 24382103

Monthly haemostatic factor variability in women and men.

Alison M Hill1, Paul W Stewart, Mark K Fung, Penny M Kris-Etherton, Henry N Ginsberg, Russell P Tracy, Thomas A Pearson, Michael Lefevre, Roberta G Reed, Patricia J Elmer, Stephen Holleran, Abby G Ershow.   

Abstract

BACKGROUND: Hormonal status influences haemostatic factors including fibrinogen, factor VII and plasminogen activator inhibitor (PAI-1), and concentrations differ among men, premenopausal and postmenopausal women. This study examines how phases of the menstrual cycle influence variability of fibrinogen, factor VII and PAI-1.
DESIGN: We studied 103 subjects (39 premenopausal women, 18 postmenopausal women and 46 men) during three, randomized, 8-week energy- and nutrient-controlled experimental diets in the Dietary Effects on Lipids and Thrombogenic Activity (DELTA) Study. Fasting blood samples were collected weekly during the last 4 weeks of each diet period, and haemostatic factors were quantified. Two linear mixed-effects models were used for fibrinogen, factor VII and PAI-1: one to estimate and compare group-specific components of variance, and the other to estimate additional fixed effects representing cyclical functions of day of menstrual cycle in premenopausal women.
RESULTS: Systematic cyclical variation with day of menstrual cycle was observed for fibrinogen (P < 0.0001), factor VII (P = 0.0012) and PAI-1 (P = 0.0024) in premenopausal women. However, the amplitude of cycling was small relative to the total magnitude of intra-individual variability. In addition, the intra-individual variance and corresponding coefficient of variation observed in premenopausal women did not differ from postmenopausal women and men.
CONCLUSIONS: The variability in haemostatic factors in premenopausal women is no greater than for postmenopausal women or men. Consequently, premenopausal women can be included in studies investigating haemostatic factor responses without controlling for stage of menstrual cycle.
© 2014 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Keywords:  Controlled dietary intervention; factor VII; fibrinogen; menstrual cycle; plasminogen activator inhibitor

Mesh:

Substances:

Year:  2014        PMID: 24382103      PMCID: PMC4153833          DOI: 10.1111/eci.12235

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  25 in total

1.  The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.

Authors:  I F Godsland; D Crook; R Simpson; T Proudler; C Felton; B Lees; V Anyaoku; M Devenport; V Wynn
Journal:  N Engl J Med       Date:  1990-11-15       Impact factor: 91.245

2.  Laboratory methods and quality assurance in the Cardiovascular Health Study.

Authors:  M Cushman; E S Cornell; P R Howard; E G Bovill; R P Tracy
Journal:  Clin Chem       Date:  1995-02       Impact factor: 8.327

3.  Evidence for the participation of both activated factor XII and activated factor IX in cold-promoted activation of factor VII.

Authors:  U Seligsohn; B Osterud; J H Griffin; S I Rapaport
Journal:  Thromb Res       Date:  1978-12       Impact factor: 3.944

4.  Variation of lipids and lipoproteins in premenopausal women compared with men and postmenopausal women. DELTA (Dietary Effects on Lipoproteins and Thrombogenic Activity) Investigators.

Authors:  R G Reed; P Kris-Etherton; P W Stewart; T A Pearson
Journal:  Metabolism       Date:  2000-09       Impact factor: 8.694

5.  New directions in dietary studies and heart disease: the National Heart, Lung and Blood Institute sponsored Multicenter Study of Diet Effects on Lipoproteins and Thrombogenic Activity.

Authors:  H N Ginsberg
Journal:  Adv Exp Med Biol       Date:  1995       Impact factor: 2.622

6.  Low-dose oral combination of 17beta-estradiol and norethisterone acetate in postmenopausal women decreases factor VII, fibrinogen, antithrombin and plasminogen activator inhibitor-1.

Authors:  C Borgfeldt; C Li; G Samsioe
Journal:  Climacteric       Date:  2004-03       Impact factor: 3.005

7.  Variation in energy intake during the menstrual cycle: implications for food-intake research.

Authors:  L Lissner; J Stevens; D A Levitsky; K M Rasmussen; B J Strupp
Journal:  Am J Clin Nutr       Date:  1988-10       Impact factor: 7.045

8.  The variability of and associations between measures of blood coagulation, fibrinolysis and blood lipids.

Authors:  P Marckmann; B Sandström; J Jespersen
Journal:  Atherosclerosis       Date:  1992-10       Impact factor: 5.162

9.  Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay.

Authors:  P J Declerck; M C Alessi; M Verstreken; E K Kruithof; I Juhan-Vague; D Collen
Journal:  Blood       Date:  1988-01       Impact factor: 22.113

Review 10.  Hormonal contraception and venous thromboembolism.

Authors:  Øjvind Lidegaard; Ian Milsom; Reynir Tomas Geirsson; Finn Egil Skjeldestad
Journal:  Acta Obstet Gynecol Scand       Date:  2012-07       Impact factor: 3.636

View more
  2 in total

1.  The Type and Amount of Dietary Fat Affect Plasma Factor VIIc, Fibrinogen, and PAI-1 in Healthy Individuals and Individuals at High Cardiovascular Disease Risk: 2 Randomized Controlled Trials.

Authors:  Penny M Kris-Etherton; Paul W Stewart; Henry N Ginsberg; Russell P Tracy; Michael Lefevre; Patricia J Elmer; Lars Berglund; Abby G Ershow; Thomas A Pearson; Rajasekhar Ramakrishnan; Stephen F Holleran; Barbara H Dennis; Catherine M Champagne; Wahida Karmally
Journal:  J Nutr       Date:  2020-08-01       Impact factor: 4.798

2.  Comparison of the effects of spinal epidural and general anesthesia on coagulation and fibrinolysis in laparoscopic cholecystectomy: a randomized controlled trial: VSJ Competition, 2nd place.

Authors:  Suleyman Demiryas; Turgut Donmez; Vuslat Muslu Erdem; Duygu Ayfer Erdem; Engin Hatipoglu; Sina Ferahman; Oguzhan Sunamak; Lale Yoldas Zengin; Ahmet Kocakusak
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2017-09-25       Impact factor: 1.195

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.